Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822838 | 1.00 | MAPT (0.62) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL27479603 | 0.85 | ALDH1A1 (0.58) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL8110956 | 0.84 | POLB (0.49) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL28657003 | 0.84 | MAPT (0.53) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL31270988 | 0.83 | ALOX5 (0.53) | MAPTALDH1A1CES2CES1MEN1 | |
| SCHEMBL8137824 | 0.83 | SMN1; SMN2 (0.52) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL31103641 | 0.82 | MEN1 (0.76) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL1572442 | 0.82 | MEN1 (0.76) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL7656493 | 0.82 | CES2 (0.70) | MAPTALDH1A1CES2CES1TP53 | |
| SCHEMBL4721013 | 0.82 | CES2 (0.70) | MAPTALDH1A1CES2CES1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079759-A1 | NOVEL SINGLE STEP ESTERIFICATION PROCESS OF ALDEHYDES USING A HETEROGENEOUS CATALYST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| EP-1212305-A2 | 1,5-BENZODIAZEPINE DERIVATIVES AS CCK-A RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-0756602-B1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5795887-A | Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds | GLAXO WELLCOME INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5739129-A | AGONIST ACTIVITY | GLAXO WELLCOME INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0756602-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| EP-0755394-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5585376-A | 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic activity | GLAXO WELLCOME INC. (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0694040-A1 | 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY | GLAXO WELLCOME INC. (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1995028399-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028419-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1994024151-A1 | 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MAPT 2392/4885ALDH1A1 2641/4885CES2 3915/4885 |
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | MAPT 18/4885ALDH1A1 4018/4885CES2 554/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MAPT 2392/4885ALDH1A1 2641/4885CES2 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.